Biopharmaceutical manufacturing depends on precision. Every process demands purity, yield, and scalability, but conventional resins often force scientists to compromise. “We innovate through collaboration. Every resin we bring to market is shaped by customer input and developed on our established agarose-based platform. This approach allows Bio-Works to meet evolving purification needs with solutions that are proven, scalable, and ready for real-world manufacturing.” The company combines classic chromatography expertise with a practical, application-driven mindset and has redefined chromatography through its custom resin solutions built for exact performance and reliable scale-up. “We focus on scalability from day one, using the same base chemistry from development to commercial scale to de-risk tech transfer,” says Lone Carlbom, CEO. Its products stand out as innovative and cutting-edge, with exceptional performance. The company merges deep chromatography expertise with practical process insight. Bio-Works develops agarose-based chromatography resins that achieve exceptional purity and capacity across every bioprocessing stage. Each resin design begins with the target molecule and process economics, resulting in products that deliver consistent flow, pressure stability, and easy cleaning. Its WorkBeads product line maintains the same base chemistry from R&D to commercial production, eliminating risk during scale-up and ensuring reproducible results. Behind these solutions stands a disciplined quality framework. Bio-Works operates under an ISO 9001:2015-certified management system that documents every step, from raw materials to finished resin, ensuring full traceability. Suppliers are qualified through ESG-based supplier evaluation and controlled document discipline anchored in a clear Supplier Code of Conduct. Every operational change follows formal risk assessment and advance customer notification to maintain transparency and control.

Targeted gene therapy is entering a new phase shaped by innovative biological design. Accurate delivery systems that can place RNA where it will have the most significant effect are integral to this shift. The natural abilities of extracellular vesicles (EV) position them as an appealing foundation for more refined treatments. EVis Bioscience is advancing targeted RNA therapeutics through a hybrid system that transforms EVs into a highly efficient and precise delivery method. The vesicles’ inherent stability and targeting provide a more consistent, sharply directed mode of RNA transport. “Our technology is promising and highly efficient, opening new avenues for using EVs in RNA therapeutics,” says Elita Montanari, co-founder and CTO. Despite their strong potential, EVs were not a dependable delivery option due to their biological constraints. During RNA loading, earlier methods struggled with aggregation or structural damage, especially given RNA’s negative charge, size and sensitivity, erasing the very properties that made them valuable. EVis Bioscience addresses this through an approach that partially fuses lipid nanovectors (LNV) with EVs. The LNVs encapsulate the RNA payload and merge with the vesicles at neutral pH and body temperature within minutes. By enabling quick fusion, the platform avoids these issues while achieving the high consistency needed for therapeutic development. More than 90 per cent of particles fuse cleanly, eliminating purification steps, while maintaining surface proteins and structural stability. The formulation benefits from materials already used in FDA-approved applications, supporting smoother progress..

The future of liquid nutraceuticals comes to life at Valentis. For more than a century, Valentis has elevated the standard of liquid supplements through strong absorption science, a deep respect for nature and a belief that natural ingredients can help people become stronger, recover faster and live better. Over time, this legacy has shaped Valentis into one of the largest food supplement manufacturers in the Baltic States and a full-scale production partner with in-house laboratory testing, primary and secondary packaging and a strong R&D engine. “Our objective is to create healthy moments in people’s lives through the products we create,” says Linas Kamarauskas, Business Development Manager. Science Behind the Difference Valentis pursues its goal by bringing together nature and science. Liquid formats often rely on clean raw materials, balanced dosing, multi-year stability and great taste. The pursuit for excellence in this led Valentis to one of its breakthroughs, the patented MiosolTM microencapsulation technology..

Specimen transport is a crucial factor in life-science research. Responsibility runs through every handoff, every mile and every hour, all of which can influence study or therapy outcomes. General logistics models are not built for this. Bookings take too long, temperature stability falters, customs delays interrupt timelines, and limited in-transit visibility leaves scientists without assurance. Arca BioLogistics sets new standards for safe, reliable transport of critical life-science materials across global supply chains. What mechanisms does Arca BioLogistics use to reduce risk in global life-science specimen transport? The logistics expert simplifies the journey through its advanced Arca Live platform that integrates quoting, booking, shipment creation, customs documentation and GPS-based tracking. It replaces the traditional chain of emails, forms and manual checks with a single, continuous workflow. How is regulated shipment planning, documentation and tracking orchestrated within the Arca Live platform? High-performance packaging and live monitoring are standard for every shipment. Pairing them with GDP-compliant operations, specialist couriers and access to temperature-controlled vehicles, clients get a seamless and safe export, import and third-country movement experience..